Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $64,093.84 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 2,831 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $22.64, for a total value of $64,093.84. Following the sale, the chief financial officer now directly owns 46,799 shares in the company, valued at approximately $1,059,529.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Akero Therapeutics Stock Performance

Shares of AKRO opened at $23.98 on Friday. The company has a market cap of $1.66 billion, a PE ratio of -7.49 and a beta of -0.31. The firm has a 50-day moving average of $20.83 and a 200-day moving average of $22.35. Akero Therapeutics, Inc. has a one year low of $11.25 and a one year high of $56.66. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12 and a quick ratio of 30.12.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.90) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.90). As a group, equities analysts forecast that Akero Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AKRO has been the topic of a number of research analyst reports. UBS Group raised their price target on Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Bank of America began coverage on shares of Akero Therapeutics in a research note on Monday, April 22nd. They issued a “neutral” rating and a $30.00 price target on the stock. Wolfe Research began coverage on shares of Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a research report on Wednesday. Finally, Canaccord Genuity Group cut their target price on Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Akero Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds have recently added to or reduced their stakes in AKRO. Janus Henderson Group PLC raised its position in shares of Akero Therapeutics by 42.2% in the first quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock valued at $154,589,000 after purchasing an additional 1,815,569 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Akero Therapeutics by 10.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after buying an additional 384,555 shares in the last quarter. Alkeon Capital Management LLC increased its holdings in Akero Therapeutics by 8.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,767,380 shares of the company’s stock valued at $190,554,000 after buying an additional 300,000 shares during the period. Vanguard Group Inc. raised its position in shares of Akero Therapeutics by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after buying an additional 584,875 shares in the last quarter. Finally, RTW Investments LP bought a new stake in shares of Akero Therapeutics during the 4th quarter worth approximately $83,891,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.